APLN and neoplasm: By generating subcutaneous xenografts, we found that APLN knockdown in tumor cells, as well as the loss-of-APLN, in the tumor microenvironment significantly reduced VLD by 36% (U87AKDAPLNWT) and 48% (in U87NSCAPLNKO), respectively, as compared to U87NSCAPLNWT controls (Figure 5).